Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur Rev Med Pharmacol Sci ; 27(20): 10069-10075, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37916377

RESUMEN

OBJECTIVE: High-pressure physiological saline isotonic solution (HPpSIS) delivery into the nasal cavity was found to modulate the local expression of immune cells, increase NGF protein, and enhance the NGF receptors' expression. Since the nasal cavity directly communicates with the eye and as NGF was previously found to ameliorate the symptoms of dry eye when topically delivered, the aim of this study was to establish whether the HPpSIS might ameliorate ocular dryness and tear film composition. SUBJECTS AND METHODS: This is an observational self-controlled case study carried out on 16 patients with dry-eye diagnosis, concerning 3-month self-administration of HPpSIS and two serial assessments of the ocular surface and tear film. OSDI questionnaire was used for ocular symptoms of dryness. BUT and Schirmer tests were used for qualitative and quantitative tear film analysis. The lipid composition was also examined. R-studio was employed for the detection of the difference between the pre- and post-analysis. RESULTS: On the basis of the OSDI questionnaire, the study population was divided into severe (61.1%), moderate (5.5%), and mild (16.6%) dry-eye symptoms. OSDI score was significantly reduced after HPpSIS (p<0.05). BUT and TMH values also ameliorated after HPpSIS (p>0.05), although not significantly. The lipid layer improved statistically (p<0.05) and correlated positively with OSDI grading. The variability of presentation in the numerical distribution before and after therapy suggests poor test sensitivity. CONCLUSIONS: HPpSIS showed a positive effect in reducing OSDI scores and ameliorating tear film quality. The possibility of an endogenous HPpSIS-induced NGF should be taken into account in dry-eye therapy.


Asunto(s)
Síndromes de Ojo Seco , Humanos , Proyectos Piloto , Síndromes de Ojo Seco/tratamiento farmacológico , Síndromes de Ojo Seco/diagnóstico , Lágrimas , Solución Salina , Soluciones Isotónicas/metabolismo , Lípidos
2.
Allergol Immunopathol (Madr) ; 44(6): 504-511, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27707587

RESUMEN

BACKGROUND: OM-85 is an immunostimulant bacterial lysate, which has been proven effective in reducing the number of lower airways infections. We investigated the efficacy of the bacterial lysate OM-85 in the primary prevention of a murine model of asthma. METHODS: In the first phase of our study the animals received doses of 0.5µg, 5µg and 50µg of OM-85 through gavage for five days (days -10 to -6 of the protocol), 10 days prior to starting the sensitisation with ovalbumin (OVA), in order to evaluate the results of dose-response protocols. A single dose (5µg) was then chosen in order to verify in detail the effect of OM-85 on the pulmonary allergic response. Total/differential cells count and cytokine levels (IL-4, IL-5, IL-13 and IFN-γ) from bronchoalveolar lavage fluid (BALF), OVA-specific IgE levels from serum, lung function and lung histopathological analysis were evaluated. RESULTS: OM-85 did not reduce pulmonary eosinophilic response, regardless of the dose used. In the phase protocol using 5µg/animal of OM-85, no difference was shown among the groups studied, including total cell and eosinophil counts in BALF, serum OVA-specific IgE, lung histopathologic findings and lung resistance. However, OM-85 decreased IL-5 and IL-13 levels in BALF. CONCLUSIONS: OM-85, administered in early life in mice in human-equivalent doses, does not inhibit the development of allergic pulmonary response in mice.


Asunto(s)
Asma/prevención & control , Extractos Celulares/administración & dosificación , Eosinófilos/efectos de los fármacos , Animales , Asma/inmunología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Eosinófilos/inmunología , Femenino , Humanos , Inmunización , Inmunoglobulina E/sangre , Ratones , Ratones Endogámicos BALB C
3.
Exp Parasitol ; 156: 95-103, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26093162

RESUMEN

It is not currently clear whether different parasites have distinct effects on the airway inflammatory response in asthma and whether exposure in early life to helminths have a stronger impact in a potential inhibitory effect on asthma. The aim of this study is to evaluate the effect of exposure to different helminth extracts on the development of allergic pulmonary response in mice, including early-life exposure. Different helminth extracts (Angiostrongylus costaricensis, Angiostrongylus cantonensis and Ascaris lumbricoides) were studied in female adult BALB/c and C57BL/6 IL-10-deficient mice in a protocol of murine asthma, injected intraperitoneally in different periods of exposure (early, pre-sensitization and post-sensitization). Cell counts in bronchoalveolar lavage (BAL), eosinophil peroxidase (EPO) from lung tissue, cytokine levels from BAL/spleen cell cultures, and lung histology were analyzed. Airway cellular influx induced by OVA was significantly inhibited by extracts of A. cantonensis and A. lumbricoides. Extracts of A. lumbricoides and A. costaricensis led to a significant reduction of IL-5 in BAL (p < 0.001). Only the exposure to A. lumbricoides led to an increased production of IL-10 in the lungs (p < 0.001). In IL-10-deficient mice exposed to A. costaricensis pre-sensitization, eosinophil counts and IL-5 levels in BAL and EPO in lung tissue were significantly reduced. In the early exposure to A. cantonensis, lung inflammation was clearly inhibited. In conclusion, different helminth extracts inhibit allergic lung inflammation in mice. IL-10 may not play a central role in some helminth-host interactions. Early exposure to helminth extracts could be a potential strategy to explore primary prevention in asthma.


Asunto(s)
Angiostrongylus/inmunología , Ascariasis/inmunología , Ascaris lumbricoides/inmunología , Asma/inmunología , Interleucina-10/inmunología , Infecciones por Strongylida/inmunología , Factores de Edad , Angiostrongylus cantonensis/inmunología , Animales , Ascariasis/complicaciones , Asma/etiología , Asma/prevención & control , Líquido del Lavado Bronquioalveolar/citología , Líquido del Lavado Bronquioalveolar/inmunología , Recuento de Células , Citocinas/análisis , Modelos Animales de Enfermedad , Eosinófilos/citología , Femenino , Interleucina-10/deficiencia , Pulmón/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Infecciones por Strongylida/complicaciones
4.
Open Ophthalmol J ; 7: 20-3, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23898355

RESUMEN

PURPOSE: To evaluate the position stability of a phakic intraocular lens (Cachet pIOL; Alcon, Laboratories, Inc., Fort Worth, TX) in the anterior chamber (AC) during a 6-months follow-up. METHODS: Thirty eyes of 16 subjects underwent a Cachet pIOL implantation for the correction of high myopia from -6.50 to -16.00 D with plano targeted refraction. The position stability of the Cachet pIOL was evaluated using an Anterior Segment-OCT (AS-OCT, Carl Zeiss AG, Oberkochen, Germany) at 1- and 6-months postoperatively. Three measurements have been taken into account: 1) the minimum distance between the anterior surface of the Cachet pIOL optic disk and the central corneal endothelium; 2) the minimum distance between the optic disk's edges of the pIOL and the endothelium; 3) the minimum distance between the posterior surface of the pIOL optic disk and the anterior surface of the crystalline lens. The endothelial cell density (ECD) was also recorded. RESULTS: No statistically significant changes of the Cachet pIOL position in the AC were found during follow-up. The average changes were ≤0.1 mm between 1- and 6-months postoperatively (P>0.05). At the end of follow-up, The mean ECD loss was 0.7 % (from 2794 ± 337 cell/mm(2) to 2776 ± 388 cell/mm(2); P>0.05). CONCLUSION: A high position stability of the Cachet pIOL in the anterior chamber was shown during a 6-months follow-up.

5.
Br J Ophthalmol ; 89(6): 689-93, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15923503

RESUMEN

AIM: To evaluate changes in corneal polarisation properties and their influence on peripapillary retinal nerve fibre layer (RNFL) thickness measurements after laser assisted in situ keratomileusis (LASIK) by means of scanning laser polarimetry (SLP) with variable corneal polarisation compensator (VCC) in normal white subjects. METHODS: SLP was performed by means of GDx VCC on 32 eyes of 32 normal subjects who underwent LASIK for ametropia correction. Corneal polarisation axis and magnitude and RNFL thickness were measured before and 8 days after LASIK. RNFL thickness data and corneal polarimetric data of one randomly selected eye per subject were analysed by the Wilcoxon signed ranks test. Correlations between corneal ablation depth, corneal polarimetric changes, and RNFL thickness changes were investigated using Spearman's rho test. RESULTS: The corneal polarisation axis significantly shifted from 15.1 degrees (17.0 degrees ) to 6.9 degrees (12.9 degrees ) (p = 0.00006) after LASIK and this change showed a strong correlation with corneal ablation depth (rho = -0.7, p = 0.00002). Among GDx parameters, TSNIT, SUP, and SD showed significant changes after LASIK and for SUP and SD these changes were well correlated with the shift in corneal polarisation axis (rho = 0.54, p = 0.03 and rho = 0.45, p = 0.01, respectively). SUP and SD changes were neutralised after compensating for corneal polarimetric changes but not TSNIT changes. NFI, a discriminating parameter, was found to be affected after LASIK only after compensating for corneal polarimetric changes. CONCLUSIONS: LASIK induces a shift in corneal polarisation axis which is responsible for inaccuracies in RNFL thickness measurements. A customised compensation for corneal polarimetric changes after LASIK allows normalisation of some of the thickness parameters except for TSNIT and NFI.


Asunto(s)
Córnea/fisiopatología , Queratomileusis por Láser In Situ , Procedimientos Quirúrgicos Refractivos , Células Ganglionares de la Retina/patología , Adulto , Birrefringencia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fibras Nerviosas/patología , Periodo Posoperatorio , Refracción Ocular , Errores de Refracción/patología , Errores de Refracción/fisiopatología
7.
Ophthalmologica ; 217(5): 351-7, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12913326

RESUMEN

Recent histopathologic studies have shown that mitochondria and peroxisomes of the retinal pigment epithelium may play a central role in the pathophysiology of age-related macular degeneration (AMD). We supposed that compounds which improve mitochondrial functions (mitotropic compounds) may show beneficial effects in preventing AMD. Fourteen patients affected by early AMD were treated with a mixture containing acetyl-L-carnitine (ALC), polyunsaturated fatty acids (PUFAs), coenzyme Q10 (CoQ10) and vitamin E, while an equal number of age- and sex-matched patients affected by early AMD were treated with vitamin E only. Recovery time after macular photostress, foveal sensitivity and mean defect in the visual field as well as blood lipid levels were recorded at the beginning and after 3, 6, 9, 12 and 24 months of follow-up. In the treated group, all the visual functions showed slight improvement which was evident after 3 months of treatment and remained nearly stationary by the end of 24 months. The same tests in the control group showed slow worsening. The divergence between treated and control groups became more marked with time, but the difference was not significant at any time of the follow-up. These findings suggest that the blend of ALC, PUFA, CoQ10 and vitamin E may improve retinal functions in early AMD.


Asunto(s)
Acetilcarnitina/uso terapéutico , Ácidos Grasos Insaturados/uso terapéutico , Degeneración Macular/tratamiento farmacológico , Retina/efectos de los fármacos , Ubiquinona/análogos & derivados , Ubiquinona/uso terapéutico , Vitamina E/uso terapéutico , Anciano , Antioxidantes/uso terapéutico , Coenzimas , Quimioterapia Combinada , Femenino , Humanos , Lípidos/sangre , Degeneración Macular/sangre , Degeneración Macular/fisiopatología , Masculino , Persona de Mediana Edad , Mitocondrias/efectos de los fármacos , Peroxisomas/efectos de los fármacos , Proyectos Piloto , Retina/fisiopatología , Campos Visuales/fisiología
8.
Clin Ther ; 20(5): 913-20, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9829443

RESUMEN

This randomized, patient-masked, crossover trial compared the analgesic efficacy of flurbiprofen and diclofenac in 16 patients following excimer laser photorefractive keratectomy. Patients were randomly assigned to receive one study medication after surgery on the first eye and the other medication after surgery on the second eye (approximately 30 days later). After both surgeries, patients instilled one drop of the assigned medication six times daily for the first 3 days postsurgery and one drop four times daily on postsurgery days 4 through 7. Patients assessed the intensity of postsurgical pain beginning at postsurgery hour 5 and pain relief beginning at postsurgery hour 8 and continued to do so daily thereafter. On the last day (day 7), patients rated the global efficacy of the analgesic treatment. All assessments were performed by patients using descriptor and visual ordinal scales and were recorded in diaries. Patients were queried as to the presence, severity, and duration of any adverse events. Flurbiprofen produced significantly greater reductions in pain intensity than did diclofenac at all evaluations through day 4 and significantly greater relief of pain than did diclofenac at all evaluations through day 3. Significantly more patients treated with flurbiprofen reported being pain free on days 3 and 4 (11 [69%] and 16 [100%], respectively) compared with those treated with diclofenac (3 [19%] and 9 [56%], respectively). Based on patient ratings, flurbiprofen had significantly better global analgesic activity than diclofenac. Both treatments were well tolerated. Mild and transient ocular burning after instillation was the only reported adverse event; it was reported by all patients in both study groups at approximately 50% of study visits.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Diclofenaco/uso terapéutico , Flurbiprofeno/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Queratectomía Fotorrefractiva , Adulto , Estudios Cruzados , Diclofenaco/efectos adversos , Femenino , Flurbiprofeno/efectos adversos , Humanos , Láseres de Excímeros , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...